InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,751.13
(
0.97%
)
US TECH 100
19,572.00
(
0.00%
)
Dow Jones
42,080.37
(
0.30%
)
Brent Oil
77.61
(
0.34%
)
Bitcoin
62,233.45
(
0.16%
)

Replies to post #151308 on Biotech Values

Replies to #151308 on Biotech Values
icon url

DonShimoda

10/26/12 4:36 PM

#151309 RE: jq1234 #151308

Look, I got your point I just don't think it's very convincing.
icon url

DonShimoda

10/26/12 5:02 PM

#151312 RE: jq1234 #151308

Aren't overlapping patients??? Sure that's possible but I think it is far more likely that the TKI failures are from the T315I mutation against which imatinib, nilotinib, and dasatinib are ineffective. The reason I suspect this is that Teva ran a T315I trial and got a 23% response rate (along with some nasty side effects).